ARCHIVES

Tasigna Shows High Response, PFS Benefit Compared to Gleevec in Phase III CML Study

This article is from The Cancer Letter archive.

Vol. 37 No. 12 | December 26, 2014

Download PDF Visit The Full Archive

Related Articles

In Congress: Senate Passes Bill For DOD Medical Research Funding

August 14, 1998

In Brief: Kessler Urges Cardiologists To Fight Teen Smoking; ODAC To Meet Dec. 14

December 1, 1995

Gleevec Produces 59% Response Rate In Gastrointestinal Stromal Tumors

May 25, 2001

Two Studies Suggest Positive HPV Status Can Indicate Improved Patient Outcomes

February 28, 2014

Fibrolast Interferon Contract Signed

May 2, 1980

House Committee Probes NCI $5.2 Billion Sole-Source Contract With SAIC-Frederick.

November 14, 2008